Sterimax Inc Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Sterimax Inc Pharmaceutical Import Records from India — 3 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sterimax Inc — Pharmaceutical Importer Profile (2026) | 3 Products, $1.9M Trade | TransData Nexus

Sterimax Inc

Pharmaceutical Importer · Canada · Gastrointestinal Focus · $1.9M Total Trade · DGFT Verified

Sterimax Inc is a pharmaceutical importer based in Canada with a total trade value of $1.9M across 3 products in 3 therapeutic categories. Based on 38 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sterimax Inc sources from 13 verified Indian suppliers, with Baxter Pharmaceuticals India Private Limited accounting for 50.3% of imports.

Sterimax Inc — Import Portfolio & Supplier Network

Sterimax Inc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sterimax Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Baxter Pharmaceuticals India Private Limited	$3.3M	109	50.3%
Gland Pharma Limited	$1.8M	59	28.4%
Msn Laboratories Private Limited

What Formulations Does Sterimax Inc Import?

Formulation	Value	Ships
Labetalol hcl injection USP 100MG/20ML	$248.5K	8
Vocarvi (foscarnet sodium injection, 24MG/ML) 6g/ 250 ML	$206.8K	5
Bupivacaine injection BP 5MG/ML 20ML	$177.4K	4
Ondansetron INJ 2MG/ML 2mlgv USP ca	$170.5K	4
Bupivacaine injection BP 0.25% (2.5 MG/ML) 20 ML glass	$169.3K	5
Bacitracin for injection USP 50000	$150.0K	3
Labetalol hcl injection USP 100MG/20ML (5MG/ML)	$149.4K	3
Bupivacainehcl in dextrose injusp(7.5MG/ML) 2ML ga ain02420 batch no.b5g0176a mfg. dt:jun-23 exp.dt:may-25 as per	$136.8K	3
Bupivacaine injection BP 0.25%(2.5MG/ML)20 ML gv	$129.4K	3
Ondansetron INJ 2MG/ML 2mlgv USP ca	$114.1K	6
Bupivacaine injection BP 0.25% (2.5MG/ML	$107.7K	3
Bupivacaine INJ BP 5MG/ml20mlgv	$103.6K	4
Bupivacaine injection BP 2.5MG/ML 10mlglass	$101.2K	3
Bupivacaine injection 5MG/ML 20 ML	$100.0K	2
Ondansetron injection 2MG/ML 2 ML	$100.0K	2

Sterimax Inc imports 138 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ondansetron	Gastrointestinal	$850.0K	17	0.7%	20
2	Furosemide	Diuretics	$700.0K	14	1.0%	15
3	Carmustine	Advanced Oncology	$350.0K	7	1.6%	2

Sterimax Inc imports 3 pharmaceutical products across 3 categories into Canada totaling $1.9M.

Sterimax Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sterimax Inc. is a privately held Canadian pharmaceutical company headquartered in Oakville, Ontario. Established in the late 1990s by Mahen (Mike) Acharya, the company specializes in the development, production, marketing, and distribution of essential hospital and retail pharmacy products across Canada. Sterimax's portfolio includes a range of generic and branded pharmaceuticals, with a particular emphasis on sterile injectables, oral solids, and other critical care medications.

The company operates with a strong commitment to enhancing the wellness of Canadians by providing high-quality, accessible medical treatments. Sterimax's product offerings span various therapeutic areas, including infectious diseases, oncology, critical care, and pain management. With a dedicated team of over 150 employees, the company has established itself as a significant player in the Canadian pharmaceutical market.

2Distribution Network

Sterimax Inc. maintains a robust distribution network to ensure the timely delivery of pharmaceutical products across Canada. The company operates multiple distribution centers strategically located to serve various regions efficiently. While specific warehouse locations are not publicly disclosed, Sterimax's infrastructure is designed to support a nationwide supply chain, facilitating prompt and reliable distribution to hospitals, clinics, and retail pharmacies.

In addition to its domestic operations, Sterimax has expanded its reach internationally, marketing a diverse and continuously growing portfolio of products throughout the Americas, Europe, and Asia. The company actively seeks established and accredited partners to handle product registration and distribution in select global markets, reflecting its commitment to broadening access to essential medications worldwide.

3Industry Role

Within Canada's pharmaceutical supply chain, Sterimax Inc. functions primarily as a pharmaceutical importer and distributor. The company sources a significant portion of its products from international suppliers, including Indian manufacturers, to meet the diverse needs of the Canadian healthcare system. Sterimax's role encompasses the procurement, importation, and distribution of pharmaceutical products, ensuring a steady supply of essential medications to various healthcare providers across the country.

By focusing on niche markets and specialized products, Sterimax has carved out a unique position in the industry, catering to specific therapeutic areas and patient needs. This strategic approach allows the company to address gaps in the market and provide critical care solutions that might otherwise be unavailable or limited in Canada.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sterimax Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sterimax Inc. demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from a select group of Indian suppliers. The top five suppliers—Baxter Pharmaceuticals India Private Limited, Gland Pharma Limited, MSN Laboratories Private Limited, Alembic Pharmaceuticals Limited, and Onesource Specialty Pharma Limited—collectively account for approximately 95% of the company's total import value from India.

This concentrated sourcing strategy may present both opportunities and risks. On one hand, it allows Sterimax to establish strong, long-term relationships with key suppliers, potentially leading to favorable terms and consistent product quality. On the other hand, such dependency could expose the company to supply chain disruptions if any of these suppliers encounter operational challenges or regulatory issues.

The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent number of shipments over the years. However, the lack of diversification in sourcing could be a strategic consideration for Sterimax to mitigate potential risks associated with over-reliance on a limited number of suppliers.

2Supply Chain Resilience

Sterimax Inc.'s supply chain resilience is closely tied to its sourcing strategy from Indian pharmaceutical manufacturers. The company's reliance on a select group of suppliers necessitates a thorough assessment of these suppliers' operational stability, regulatory compliance, and capacity to meet demand fluctuations.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the regulation of pharmaceutical products is overseen by Health Canada, the federal department responsible for promoting and maintaining the health of Canadians. Health Canada's regulatory framework ensures that drugs and health products meet rigorous standards for safety, efficacy, and quality before they are authorized for sale in the Canadian market. (canada.ca)

The primary legislation governing pharmaceutical imports is the Food and Drugs Act, along with its associated regulations. These laws stipulate the requirements for importing drugs, including the necessity for a Drug Identification Number (DIN) for each product, an Establishment Licence (EL) for importers, and compliance with Good Manufacturing Practice (GMP) standards. (canada.ca)

2Import Licensing & GMP

To import pharmaceutical products into Canada, companies must obtain an Establishment Licence (EL) from Health Canada, authorizing them to import specific categories of drugs. Each imported drug must have a Drug Identification Number (DIN), indicating that it has been reviewed and authorized by Health Canada. Additionally, the foreign manufacturing site must be listed on the importer's EL, ensuring that the manufacturing facility complies with Health Canada's GMP requirements. (canada.ca)

Recognized GMP certifications include those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential for ensuring that imported pharmaceutical products meet the necessary quality standards for the Canadian market.

Sterimax Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sterimax Inc.'s focus on importing pharmaceutical products from India, particularly in the therapeutic areas of gastrointestinal, diuretics, and advanced oncology, aligns with the company's strategic objective to provide essential medications that address critical health needs in Canada. The company's portfolio concentration, with the top five products accounting for 100% of imports, indicates a targeted approach to sourcing and distribution.

The market demand for these therapeutic areas is driven by the prevalence of related health conditions in Canada, necessitating a reliable supply of effective treatments. Sterimax's strategic sourcing from Indian manufacturers enables the company to meet this demand while maintaining cost-effectiveness and product quality.

2Sourcing Profile

Sterimax Inc. employs a sourcing strategy that emphasizes the importation of generic pharmaceutical products, particularly finished formulations such as tablets, capsules, syrups, and injections. This approach allows the company to offer a diverse range of medications across various therapeutic categories, catering to the specific needs of the Canadian healthcare market.

India's well-established pharmaceutical manufacturing sector, with its adherence to international quality standards and competitive pricing, makes it a strategic partner for Sterimax. By sourcing from India, Sterimax can ensure a consistent supply of high-quality products while managing costs effectively.

Frequently Asked Questions — Sterimax Inc

What products does Sterimax Inc import from India?

Sterimax Inc imports 3 pharmaceutical products across 3 categories. Top imports: Ondansetron ($850.0K), Furosemide ($700.0K), Carmustine ($350.0K).

Who supplies pharmaceuticals to Sterimax Inc from India?

Sterimax Inc sources from 13 verified Indian suppliers. The primary supplier is Baxter Pharmaceuticals India Private Limited (50.3% of imports, $3.3M).

What is Sterimax Inc's total pharmaceutical import value?

Sterimax Inc's total pharmaceutical import value from India is $1.9M, based on 38 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sterimax Inc focus on?

Sterimax Inc imports across 3 categories. The largest: Gastrointestinal (44.7%), Diuretics (36.8%), Advanced Oncology (18.4%).

Get Full Sterimax Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Sterimax Inc

Sterimax Inc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Sterimax Inc?

What Formulations Does Sterimax Inc Import?

What Products Does Sterimax Inc Import?

Top Products by Import Value

Sterimax Inc Therapeutic Categories — 3 Specializations